רווח נקי למניה (EPS TTM): Oruka Corp (ORKA)

Fundamental net income per share TTM visualizes the stock's profitability, where -2.48 sets the current value of the metric. Risks for Oruka Therapeutics Inc (ORKA) are linked to early-stage testing and a lack of sales amid strong industry pressure. The dermatology team is motivated by stock options and the creation of cutting-edge medicines. Business development relies on a long-term clinical research cycle that remains independent of general market trends.
פילוחים אנליטיים של חברת Oruka Therapeutics Inc (ORKA)

To identify fundamental stability drivers, investors must track the trailing 12-month earnings per share, which GURU.Markets calculates by dividing total annual income by the total number of securities. This indicator allows for an assessment of the asset's real yield, which is critical for Oruka Therapeutics Inc (ORKA) as it transitions from antibody development to extracting superprofits from patent-protected niches.